Skip to content

Kymera Therapeutics KYMR Contract Liabilities

Contract Liabilities at other companies

Exelixis logo
ExelixisEXEL

Other financials

Income statement

See full
Revenue$34.4M+55.5%
Operating income-$84.2M-13.1%
Net income-$69.2M-5.6%
EPS (diluted)-$0.71+13.4%

Balance sheet

See full
Cash & equivalents$144.1M+60.2%
Total debt$82.2M-6.5%
Total equity$1.5B+95.8%
Total assets$1.7B+81.7%

Cash flow

See full
Operating cash flow-$88.8M-12.2%
CapEx$434.0K-7.1%
Free cash flow-$89.3M-12.1%

Valuation

See full
Market cap$7.44B+283%
Enterprise value$7.38B+280%
P/S144.5×+111×

Profitability

See full
Operating margin-697.7%+635pp
Net margin-612%+602pp
FCF margin-474%+92.4pp

Returns & leverage

See full
Return on equity-27.1%-3.7pp
Debt / equity0.1×-0.1×
Current ratio10.8×+2.3×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Kymera Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kymera Therapeutics's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kymera Therapeutics's contract liabilities?
Kymera Therapeutics (KYMR) reported contract liabilities of $0 in Q1 2026.
What is the long-term trend for Kymera Therapeutics's contract liabilities?
Over 5 years (2020 to 2025), Kymera Therapeutics's contract liabilities has grown at a -31.9% compound annual growth rate (CAGR), from $77.84M to $11.44M.
What does contract liabilities mean?
Revenue collected or billed in advance of performance — deferred revenue under ASC 606 terminology, representing future revenue obligations.